Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
10.03.24 | Galderma @ AAD 2024: New Data Demonstrate the Long-Term Efficacy of Nemolizumab in Prurigo Nodularis and Its Durability in Atopic Dermatitis | 510 | Business Wire | Nemolizumab is a first-in-class investigational monoclonal antibody designed to provide relief from itch by targeting IL-31
One-year data from an interim analysis of the OLYMPIA long-term... ► Artikel lesen | |
10.03.24 | Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis | 595 | Business Wire | Randomized Phase 2 study met its primary and secondary endpoints following 16 weeks of treatment across all dosing groups, reinforcing povorcitinib's potential role in treating prurigo nodularis... ► Artikel lesen |
Suchbegriffe der letzen 24 h | Anzahl |
---|---|
TESLA | 3.794 |
NVIDIA | 3.190 |
RHEINMETALL | 2.043 |
RENK GROUP | 1.777 |
THYSSENKRUPP | 1.678 |
STEYR MOTORS | 1.616 |
BYD | 1.574 |
BAYER | 1.561 |
NEL | 1.452 |
DEUTZ | 1.442 |
TUI | 1.400 |
VOLKSWAGEN | 1.229 |
EVOTEC | 1.146 |
NOVO NORDISK | 1.129 |
MERCEDES-BENZ | 1.009 |
XIAOMI | 943 |
AMAZON | 926 |
PUMA | 890 |
PORSCHE AG | 870 |
BASF | 858 |
COMMERZBANK | 786 |
DEUTSCHE BANK | 784 |
NORDEX | 772 |
AIXTRON SE | 728 |
VONOVIA | 638 |